End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.77 CNY | +1.48% | -0.03% | -7.01% |
May. 02 | ICBC, CCB Name Deputy Party Secretaries | MT |
Apr. 12 | Tiantan Biological Products' Q1 Profit Jumps 21%; Shares Rise 7% | MT |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.87 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.01% | 6.55B | C | ||
-3.79% | 87.06B | A- | ||
+1.45% | 40.25B | A- | ||
-15.94% | 31.09B | B- | ||
+52.66% | 24.74B | A | ||
-14.50% | 15.91B | C | ||
-9.12% | 11.96B | D+ | ||
-14.38% | 11.92B | B- | ||
-42.56% | 11.61B | B | ||
+4.87% | 8.73B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600161 Stock
- Ratings Beijing Tiantan Biological Products Co., Ltd.